BACKGROUND: Children with Prader-Willi syndrome (PWS) have decreased muscle mass, hypotonia, and impaired linear growth. Recombinant human GH (hGH) treatment reportedly improves body composition and physical function in children with PWS, but these studies lack long-term control data. To assess the impact of hGH therapy begun early in life on the natural history of PWS, we compared height, body composition, and strength in similar-age children with PWS naïve to hGH with those treated with hGH for 6 yr. OBJECTIVES: Forty-eight children with PWS were studied: 21 subjects (aged 6-9 yr) treated with hGH for 6 yr (beginning at 4-32 months, mean 13 +/- 6 months) were compared with 27 children of similar age (5-9 yr) prior to treatment with hGH. Percent body fat, lean body mass, carbohydrate/lipid metabolism, and motor strength were compared using analysis of covariance. RESULTS: PWS children treated with hGH demonstrated lower body fat (mean, 36.1 +/- 2.1 vs. 44.6 +/- 1.8%, P < 0.01), greater height (131 +/- 2 vs. 114 +/- 2 cm; P < 0.001), greater motor strength [increased standing broad jump 22.9 +/- 2.1 vs. 14.6 +/- 1.9 in. (P < 0.001) and sit-ups 12.4 +/- 0.9 vs. 7.1 +/- 0.7 in 30 sec (P < 0.001)], increased high-density lipoprotein cholesterol (58.9 +/- 2.6 vs. 44.9 +/- 2.3 mg/dl, P < 0.001), decreased low-density lipoprotein (100 +/- 8 vs. 131 +/- 7 mg/dl, P < 0.01), and no difference in fasting glucose or insulin. CONCLUSIONS: hGH treatment in children with PWS, begun prior to 2 yr of age, improves body composition, motor function, height, and lipid profiles. The magnitude of these effects suggests that long-term hGH therapy favorably alters the natural history of PWS to an extent that exceeds risks and justifies consideration for initiation during infancy.
BACKGROUND:Children with Prader-Willi syndrome (PWS) have decreased muscle mass, hypotonia, and impaired linear growth. Recombinant human GH (hGH) treatment reportedly improves body composition and physical function in children with PWS, but these studies lack long-term control data. To assess the impact of hGH therapy begun early in life on the natural history of PWS, we compared height, body composition, and strength in similar-age children with PWS naïve to hGH with those treated with hGH for 6 yr. OBJECTIVES: Forty-eight children with PWS were studied: 21 subjects (aged 6-9 yr) treated with hGH for 6 yr (beginning at 4-32 months, mean 13 +/- 6 months) were compared with 27 children of similar age (5-9 yr) prior to treatment with hGH. Percent body fat, lean body mass, carbohydrate/lipid metabolism, and motor strength were compared using analysis of covariance. RESULTS:PWSchildren treated with hGH demonstrated lower body fat (mean, 36.1 +/- 2.1 vs. 44.6 +/- 1.8%, P < 0.01), greater height (131 +/- 2 vs. 114 +/- 2 cm; P < 0.001), greater motor strength [increased standing broad jump 22.9 +/- 2.1 vs. 14.6 +/- 1.9 in. (P < 0.001) and sit-ups 12.4 +/- 0.9 vs. 7.1 +/- 0.7 in 30 sec (P < 0.001)], increased high-density lipoprotein cholesterol (58.9 +/- 2.6 vs. 44.9 +/- 2.3 mg/dl, P < 0.001), decreased low-density lipoprotein (100 +/- 8 vs. 131 +/- 7 mg/dl, P < 0.01), and no difference in fasting glucose or insulin. CONCLUSIONS: hGH treatment in children with PWS, begun prior to 2 yr of age, improves body composition, motor function, height, and lipid profiles. The magnitude of these effects suggests that long-term hGH therapy favorably alters the natural history of PWS to an extent that exceeds risks and justifies consideration for initiation during infancy.
Authors: A Corrias; J Bellone; L Beccaria; L Bosio; G Trifirò; C Livieri; L Ragusa; A Salvatoni; M Andreo; P Ciampalini; G Tonini; A Crinò Journal: J Endocrinol Invest Date: 2000-02 Impact factor: 4.256
Authors: Roderick F A de Lind van Wijngaarden; Elbrich P C Siemensma; Dederieke A M Festen; Barto J Otten; Edgar G A H van Mil; Joost Rotteveel; Roelof J H Odink; G C B Karen Bindels-de Heus; Mariëtte van Leeuwen; Danny A J P Haring; Gianni Bocca; E C A Mieke Houdijk; J J Gera Hoorweg-Nijman; René C F M Vreuls; Petr E Jira; A S Paul van Trotsenburg; Boudewijn Bakker; Eelco J Schroor; Jan Willem Pilon; Jan M Wit; Stenvert L S Drop; Anita C S Hokken-Koelega Journal: J Clin Endocrinol Metab Date: 2009-10-16 Impact factor: 5.958
Authors: Andrea M Haqq; Diane D Stadler; Russell H Jackson; Ron G Rosenfeld; Jonathan Q Purnell; Stephen H LaFranchi Journal: J Clin Endocrinol Metab Date: 2003-05 Impact factor: 5.958
Authors: Dederieke A M Festen; Roderick de Lind van Wijngaarden; Marielle van Eekelen; Barto J Otten; Jan M Wit; Hugo J Duivenvoorden; Anita C S Hokken-Koelega Journal: Clin Endocrinol (Oxf) Date: 2008-03-18 Impact factor: 3.478
Authors: Roderick F A de Lind van Wijngaarden; Luuk W L de Klerk; Dederieke A M Festen; Hugo J Duivenvoorden; Barto J Otten; Anita C S Hokken-Koelega Journal: J Clin Endocrinol Metab Date: 2009-01-21 Impact factor: 5.958
Authors: Jennifer Proffitt; Kathryn Osann; Barbara McManus; Virginia E Kimonis; Janalee Heinemann; Merlin G Butler; David A Stevenson; June-Anne Gold Journal: Am J Med Genet A Date: 2018-12-19 Impact factor: 2.802
Authors: Samantha N Hartin; Waheeda A Hossain; Ann M Manzardo; Shaquanna Brown; Paula J Fite; Marco Bortolato; Merlin G Butler Journal: Growth Horm IGF Res Date: 2018-02-12 Impact factor: 2.372
Authors: Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Manuel Posada-de-la-Paz; Pedro Serrano-Aguilar; Panos Kanavos; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; Petra Baji; Claudia Delgado; Johann Matthias Graf von der Schulenburg; Ulf Persson; Karine Chevreul; Giovanni Fattore Journal: Eur J Health Econ Date: 2016-04-02